PMC:7600245 / 53619-53961
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T236 | 229-232 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T20 | 229-232 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T541 | 115-118 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T542 | 183-184 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T543 | 229-232 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T69341 | 38-48 | Chemical | denotes | famotidine | http://purl.obolibrary.org/obo/CHEBI_4975 |
| T6716 | 92-110 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T50648 | 141-151 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T399 | 0-342 | Sentence | denotes | Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1665 | 38-48 | Chemical | denotes | famotidine | MESH:D015738 |
| 1666 | 92-110 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 1667 | 141-151 | Chemical | denotes | remdesivir | MESH:C000606551 |